Ventyx Biosciences, Inc. Logo

Ventyx Biosciences, Inc.

Clinical-stage biopharma developing oral therapies for autoimmune, inflammatory & neuro diseases.

VTYX | US

Overview

Corporate Details

ISIN(s):
US92332V1070
LEI:
Country:
United States of America
Address:
12790 EL CAMINO REAL, SUITE 200, 92130 SAN DIEGO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases. Leveraging expertise in medicinal chemistry, structural biology, and immunology, the company discovers and advances differentiated small molecule therapeutics for conditions with high unmet medical need. Its pipeline includes NLRP3 inhibitors VTX2735 (Phase 2 for recurrent pericarditis) and VTX3232 (Phase 2 for neurodegenerative and cardiometabolic diseases). The inflammatory bowel disease portfolio features S1P1R modulator tamuzimod and TYK2 inhibitor VTX958, both of which have completed Phase 2 clinical trials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Ventyx Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ventyx Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ventyx Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

InMed Pharmaceuticals Inc. Logo
Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.
United States of America
INM
Inmune Bio, Inc. Logo
Develops immunotherapies reprogramming innate immunity for cancer, Alzheimer's, and inflammation.
United States of America
INMB
INOVIO PHARMACEUTICALS, INC. Logo
Develops DNA medicines delivered via smart devices for cancer, HPV, and infectious diseases.
United States of America
INO
Insight Molecular Diagnostics Inc. Logo
Develops molecular diagnostic tests for oncology and transplant monitoring for clinicians & researchers.
United States of America
IMDX
INSMED Inc Logo
Develops and commercializes innovative therapies for serious and rare diseases.
United States of America
INSM
Instil Bio, Inc. Logo
Developing autologous TIL cell therapies using a patient's own immune cells to fight solid tumors.
United States of America
TIL
Intellia Therapeutics, Inc. Logo
Developing curative CRISPR/Cas9 genome editing therapies for severe genetic disorders.
United States of America
NTLA
Intercure Ltd. Logo
Develops and distributes pharmaceutical-grade medical cannabis for patients and pharmacies globally.
Israel
INCR
Intervacc AB Logo
Develops recombinant protein vaccines and diagnostics for animal health, like Strangvac® for horses.
Sweden
IVACC
iNtRON Biotechnology, Inc. Logo
Develops phage therapeutics and molecular diagnostics to combat infectious diseases.
South Korea
048530

Talk to a Data Expert

Have a question? We'll get back to you promptly.